Develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 198% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.9× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
Over the last 4 years, sales grew about 198% a year on average.
Sales run at $146.4M a year. A small number, but proof the product has real buyers.
A loss of $60.5M against $146.4M in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Costs swallow the gains that sales growth brings in. Council score: 4/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown, the price history.